ResearcherCentral South UniversityActive in the last 2 years

Kai Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1544-5518; OpenAlex author ID A5115602431. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 4

Metabolic syndrome worsens perioperative and oncological outcomes in patients with pancreatic ductal adenocarcinoma after R0 resection: A multicenter propensit… Co-author DOI 10.1016/j.hbpd.2026.06.001 ↗
Retraction notice to "LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p" [Biomed. Pharmacother. 114 (2019) 108862]. Co-author DOI 10.1016/j.biopha.2024.116188 ↗
Novel perspective in pancreatic cancer therapy: Targeting ferroptosis pathway. Last author DOI 10.4251/wjgo.v13.i11.1668 ↗
CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer. Co-author DOI 10.1007/s00262-020-02500-3 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Songyang Liu · 2 shared papers, 2020–2024 · strength 0.47
- Paper Retraction notice to "LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p" [Biomed. Pharma… DOI 10.1016/j.biopha.2024.116188 ↗
- Paper CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancr… DOI 10.1007/s00262-020-02500-3 ↗
Yahui Liu · 1 shared paper, 2024 · strength 0.31
- Paper Retraction notice to "LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p" [Biomed. Pharma… DOI 10.1016/j.biopha.2024.116188 ↗
Peizi Liu · 1 shared paper, 2026 · strength 0.25
- Paper Metabolic syndrome worsens perioperative and oncological outcomes in patients with pancreatic ductal adenocarcinoma aft… DOI 10.1016/j.hbpd.2026.06.001 ↗
Xiuping Zhang · 1 shared paper, 2026 · strength 0.25
- Paper Metabolic syndrome worsens perioperative and oncological outcomes in patients with pancreatic ductal adenocarcinoma aft… DOI 10.1016/j.hbpd.2026.06.001 ↗
Zhiming Zhao · 1 shared paper, 2026 · strength 0.25
- Paper Metabolic syndrome worsens perioperative and oncological outcomes in patients with pancreatic ductal adenocarcinoma aft… DOI 10.1016/j.hbpd.2026.06.001 ↗
Rong Liu · 1 shared paper, 2026 · strength 0.25
- Paper Metabolic syndrome worsens perioperative and oncological outcomes in patients with pancreatic ductal adenocarcinoma aft… DOI 10.1016/j.hbpd.2026.06.001 ↗
Yingchao Wang · 1 shared paper, 2020 · strength 0.16
- Paper CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancr… DOI 10.1007/s00262-020-02500-3 ↗
Wei Zhang · 1 shared paper, 2020 · strength 0.16
- Paper CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancr… DOI 10.1007/s00262-020-02500-3 ↗
Yang Yang · 1 shared paper, 2021 · strength 0.15
- Paper Novel perspective in pancreatic cancer therapy: Targeting ferroptosis pathway. DOI 10.4251/wjgo.v13.i11.1668 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.